What is Synagis® immunization?

Synagis®, also called palivizumab, is an antibody produced by recombinant DNA technology that was first introduced in the U.S. market in 1998. It is approved for use in preventing severe lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants and children younger than 24 months of age. It is not a treatment for established RSV infection.

Synagis® is given as an intramuscular injection every month during the fall, winter, and early spring months.

Munson Medical Center provides Synagis® immunization at the Specialty Clinics twice monthly from November through April with a physician's referral.

What is RSV?

RSV is a common cold virus that most children will have evidence of by the age of two years. It usually occurs during the late fall, winter, or early spring months and is easily spread from respiratory secretions through close contact with infected persons, or contact with contaminated surfaces or objects. Illness begins most frequently with fever, runny nose, cough, and sometimes wheezing. Symptoms are variable and differ with age. Premature infants and those with underlying lung or heart conditions are most at risk for developing severe RSV illness, and are those whom the immunizations with Synagis® are appropriate.

Should my infant receive Synagis® immunizations?

The American Academy of Pediatrics has published criteria for who should receive Synagis® immunizations. It includes:

• Certain infants with chronic lung disease
  
• Certain infants with congenital heart disease
  
• Infants who are born prematurely (less than 32 weeks gestational age) and are less than 6-12 months of age at the start of the RSV season (usually November)
  
• Infants who are born prematurely between 32 and 35 weeks gestational age and are less than 6 months of age at the start of RSV season with other risk factors, such as exposure to environmental air pollutants, day-care attendance, school age siblings, or congenital abnormalities of the airways

It is important that you discuss this question with your infant's physician. Your physician will make the final recommendation as to whether your infant should receive Synagis®.

What are Synagis® side effects?

The place where the shot is given may become red or tender. Rarely, side effects may include vomiting or diarrhea, cold symptoms, ear infections, rash, or pain. As with any medicine, there is risk of an allergic reaction. Make sure to discuss your concerns and questions with your health care provider.

If you are a Munson Healthcare patient and have a compliment, concern, or complaint, please contact one of our Patient Liaisons.

We welcome your comments and suggestions about this Web site.